Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

30 Jan 2014

Viewpoints: High court weighs home health care workers' union rights; abortion protections becoming 'all but meaningless'

On Tuesday, the justices were presented with a golden opportunity to further increase inequality. The court heard arguments in Harris v. Quinn, a case testing whether home-care providers who work under a union contract with the state of Illinois can avoid paying dues that support the union's collective-bargaining work.

23 Jan 2014

Longer withdrawal times during colonoscopy correlates with higher rate of polyp detection

Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) researchers found that longer withdrawal times during a colonoscopy correlates with a higher rate of polyp detection. The study was recently published online in in the American Journal of Gastroenterology.

22 Jan 2014

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

The Damon Runyon Cancer Research Foundation announced that six scientists with novel approaches to fighting cancer have been named 2014 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

21 Jan 2014

Surgeon general: Smoking linked to more than 30 diseases, conditions

The report, which finds that smoking causes even more physical and financial damage than previously estimated, was released 50 years after the first report tied cigarettes to diseases.

20 Jan 2014

Tumor profiling study of colorectal cancer to be presented at 2014 Gastrointestinal Cancers Symposium

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence, this study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer.

18 Jan 2014

First Edition: January 17, 2014

Today's headlines include reports from Capitol Hill about passage of a $1.1 billion spending bill as well as testimony by an Obama administration official about healthcare.gov

17 Jan 2014

Study shows high-fiber diet reduces risk of colon problems

Scientists have more reasons for you to eat fiber and not abuse antibiotics.

17 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

US underestimated its progress in war on cancer, say Dartmouth researchers

Since the enactment of the National Cancer Act in 1971, the U.S. has spent hundreds of billions of dollars in cancer research and treatment. And yet, the cancer mortality rate-the historic benchmark of progress-has only declined modestly while the mortality rates of other leading causes of death have declined substantially. This difference has led many to question whether we've made progress in the 'War on Cancer'. The answer is definitively yes according to Norris Cotton Cancer Center research published Monday in the Journal of Clinical Oncology.

16 Jan 2014

International study develops refined method to identify individuals at risk for certain inherited cancer

An international study has developed a refined method to identify people at risk for certain inherited cancer as a result of Lynch syndrome.

15 Jan 2014

Lifestyle changes and screening tools prove to reduce cancer risk, says doctor

President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.

10 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

Researchers develop new tool that accurately predicts individual's risk of colorectal cancer

Researchers at Cleveland Clinic have developed a new tool called CRC-PRO that allows physicians to quickly and accurately predict an individual's risk of colorectal cancer, as published in the current edition of the Journal of the American Board of Family Medicine.

5 Jan 2014

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Study finds milk serves as protective carrier of bioactive molecules

Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science- finds that when epigallocatechin gallate (EGCG), the major extractable polyphenol in green tea and the most biologically active, when diluted in skim milk or other milk complexes remains bioactive and continues to reduce colon cancer cell proliferation in culture at concentrations higher than 0.03 mg of EGCG/mL.

20 Dec 2013

Patient assessment of clinical services quality predicts survival for colorectal cancer patients

Patient assessment of clinical services quality was shown to be an independent predictor of survival for colorectal cancer patients in a study recently published in the Journal of Healthcare Quality, the peer reviewed publication of the National Association for Healthcare Quality (NAHQ), www.nahq.org.

20 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

Viewpoints: High court weighs home health care workers' union rights; abortion protections becoming 'all but meaningless'

Longer withdrawal times during colonoscopy correlates with higher rate of polyp detection

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

Surgeon general: Smoking linked to more than 30 diseases, conditions

Tumor profiling study of colorectal cancer to be presented at 2014 Gastrointestinal Cancers Symposium

First Edition: January 17, 2014

Study shows high-fiber diet reduces risk of colon problems

Biothera enhances innate immune responses to Imprime PGG drug candidate

US underestimated its progress in war on cancer, say Dartmouth researchers

International study develops refined method to identify individuals at risk for certain inherited cancer

Lifestyle changes and screening tools prove to reduce cancer risk, says doctor

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Researchers develop new tool that accurately predicts individual's risk of colorectal cancer

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Study finds milk serves as protective carrier of bioactive molecules

Patient assessment of clinical services quality predicts survival for colorectal cancer patients

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Industry Focus - Oncology (1st Edition) eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Industry Focus - Oncology (1st Edition) eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in